Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06120270
Other study ID # LT/TS/276I-2023-01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 3, 2023
Est. completion date July 2027

Study information

Verified date April 2024
Source Lifetech Scientific (Shenzhen) Co., Ltd.
Contact KaDirr Shemsi, PM
Phone 17621309203
Email KaDirr@lifetechmed.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to compile real-world data on patient outcomes and evaluate the procedural success and performance of the CeraFlex™ PFO Closure System.


Description:

This is a multicenter, prospective, observational, single-arm, open-label, post-market Study. The study device is the Lifetech CeraFlex PFO closure system, which is composed of a) CeraFlex PFO Occluder, and b) SteerEase Introducer. The PFO Closure System is indicated for the non-surgical closure of Patent Foramen Ovale (PFO), and the study objective is to collect real-world data on patient outcomes and evaluate the procedural success and performance of the CeraFlex PFO Closure System. The estimated enrollment period is approximately 18 months, and each subject will followed 24 months post-procedure. The assessment schedule at discharge, 1-3 months follow-up, 6 months follow-up, 12 months follow-up, and 24 months follow-up. Electronic Date Capture (EDC) System will be used for this Study.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date July 2027
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Patient with indication(s) for PFO Occluder Closure in the Instruction For Use (IFU): 1. Confirmed PFO by medical examinations; 2. Associated with recurrent migraine/headache or TIA or cryptogenic stroke. 2. Patient characteristics consistent with the corresponding IFU & Device Size Selection: 1. Measure the distance from the defect to the aorta root; 2. Measure the distance from the defect to the superior vena cava (SVC) rim; select a device with the radius of the right disc that will not exceed the lesser of these two distances. 3. Patients who are willing to comply with all study procedures and be available for the duration of the study. 4. Patients or legally authorized representative(s) who are willing and capable of providing informed consent. Exclusion Criteria: 1. Age <18 years or Age >85 years. 2. Patient with a history of ongoing Atrial Fibrillation (AF). 3. Patient with malignancy or other illness where life expectancy is less than 1 year. 4. Patient not covered by a social security scheme. 5. Patients who are participating in an investigational drug or device study currently. 6. Women of childbearing potential who are, or plan to become pregnant during the time of the study (method of assessment upon physician's discretion). 7. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. 8. Any contraindication mentioned in the corresponding IFU: 1. Patients known to have intracardiac thrombi, especially left atrial or left atrial appendage thrombi, demonstrated by echocardiography. Patients known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy unless another anti-platelet agent can be administered for 6 months. 2. Anatomy in which the CeraFlexTM PFO device of the required size would interfere with intra-cardiac structure or intra-vascular structure, such as a pulmonary vein, or aorta root. 3. Patients whose heart or vein size is too small to allow TEE probing or catheterization. 4. Patients who are in the condition, e.g. active infection, which would cause them to be poor candidates for cardiac catheterization. 5. Patients known to have sepsis within one month prior to implantation, or any systemic infection that cannot be successfully treated prior to device placement. 6. Patients whose heart does not have enough tissue to secure the device. 7. Patients with hypercoagulation disease. 8. Any patient for whom the radius of the device is greater than the distance from the patent foramen ovale to the aortic root or superior vena cava. - No contraindications specified in the SteerEase introducer IFU.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CeraFlex PFO Closure System
The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).

Locations

Country Name City State
Germany Kardiologisch-Angiologische Praxis - Herzzentrum Bremen Bremen
Germany Heart Center Dresden Dresden
Germany Hospital Fürth Fürth
Germany Kath. Marienkrankenhaus gGmbH Hamburg
Germany German Heart Center Leipzig Leipzig
Germany Klinikum St. Georg gGmbH Leipzig Leipzig
Germany German Heart Center Munich Munich
Germany University clinic Tübingen Tübingen

Sponsors (1)

Lead Sponsor Collaborator
Lifetech Scientific (Shenzhen) Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural success rate Procedure success is defined as a composite of :
absence of peri-procedural stroke-related events (ischemic stroke, cryptogenic stroke, or TIA), device embolization, cardiac or vascular perforation, or death, at discharge or 7 days post-procedure, whichever comes first;
successful implantation of the device at the procedure.
Procedure/at discharge or 7 days post-procedure, whichever comes first
Secondary Residual shunt Residual shunt was classified on the basis of the estimated number of microbubbles detected in the left atrium within three cardiac cycles after appearance in the right atrium, as observed on cTTE/cTEE while the patient was at rest or during Valsalva procedure. The presence of 0 microbubbles was classified as no shunt, 1 to 5 microbubbles as small, 6 to 25 microbubbles as moderate, and more than 25 microbubbles as large. At procedure, 6 months and 12 months post-implantation
Secondary Rate of stroke related events Ischemic stroke, cryptogenic stroke, or TIA From attempted procedure up to 24 months post-implantation
Secondary Rate of Device Deficiencies Including device malfunctions, failures, and non-conformances From attempted procedure up to 24 months post-implantation
Secondary Incidence of Serious Adverse Event SAE From attempted procedure up to 24 months post-implantation
Secondary Incidence of death Death From attempted procedure up to 24 months post-implantation
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT04610463 - Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism N/A
Completed NCT02882815 - Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder N/A
Completed NCT04604015 - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt N/A
Active, not recruiting NCT04950192 - Philips Intracardiac Echocardiography (ICE) Clinical Registry
Not yet recruiting NCT04549272 - Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale
Completed NCT02621528 - Lifetech CeraFlex™ Post-Market Surveillance Study N/A
Terminated NCT01018355 - The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI N/A
Completed NCT00831259 - Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO) N/A
Not yet recruiting NCT05360771 - Study on the Safety and Effectiveness of the SnowyTM PFO Closure System N/A
Recruiting NCT05546320 - Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale Phase 4
Recruiting NCT05561660 - COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2) Phase 4
Completed NCT03904277 - Does Patent Foramen Ovale Size Matter in Men and Women
Terminated NCT01773252 - Right to Left Cardiac Shunt Detection Phase 3
Completed NCT01216423 - Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale N/A
Completed NCT03377465 - Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis N/A
Active, not recruiting NCT04738071 - International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry
Not yet recruiting NCT06413147 - Long-term Procedural and Device Related Complications of PFO Closure
Not yet recruiting NCT06344494 - Cardiac Interventional ICE Imaging Trial N/A
Withdrawn NCT02378623 - Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli Phase 2